Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Triple Negative Breast Neoplasms × Leucovorin × Clear all

Phase

Status

Terminated 2 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 17 Rectal Neoplasms 10 Colonic Neoplasms 9 Neoplasm Metastasis 3 Carcinoma, Hepatocellular 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Pancreatic Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sezary Syndrome 1 Sarcoma 1 Retinoblastoma 1 Pancreatic Adenocarcinoma Metastatic 1 Neuroblastoma 1 Neoplasms 1 Mycosis Fungoides 1 Motor Activity 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Immunoblastic Lymphadenopathy 1 Gastrointestinal Neoplasms 1 Esophagogastric Cancer 1 Esophageal Neoplasms 1 Colorectal Adenocarcinoma Metastatic to the Liver 1 Clinical Stage I Gastric Cancer AJCC v8 1 Choroid Plexus Neoplasms 1

Interventions

Paclitaxel 6 pembrolizumab 5 Doxorubicin 4 Cyclophosphamide 4 130-nm albumin-bound paclitaxel 3 olaparib 2 glembatumumab vedotin 2 durvalumab 2 Carboplatin 2 yeast-CEA vaccine 1 trifluridine tipiracil drug combination 1 tremelimumab 1 trastuzumab duocarmazine 1 tislelizumab 1 taxane 1 talazoparib 1 sacituzumab govitecan 1 sabizabulin 1 parsaclisib 1 mirvetuximab soravtansine 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 brigimadlin 1 bavituximab 1 avelumab 1 atezolizumab 1 X-Rays 1 Vorinostat 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡